[1]王玉峰,曾 嘉,何东风.碘化油化疗药物乳剂联合D-TACE对比cTACE治疗肝细胞癌的临床价值 [J].介入放射学杂志,2022,31(08):800-804.
　WANG Yufeng,ZENG Jia,HE Dongfeng..Iodized oil chemotherapeutic drug emulsion combined with D-TACE versus c-TACE in the treatment of hepatocellular carcinoma： analysis its clinical value[J].journal interventional radiology,2022,31(08):800-804.
点击复制

碘化油化疗药物乳剂联合D-TACE对比cTACE治疗肝细胞癌的临床价值



()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年08
页码:
800-804
栏目:
临床研究
出版日期:
2022-09-30

文章信息/Info

Title:
Iodized oil chemotherapeutic drug emulsion combined with D-TACE versus c-TACE in the treatment of hepatocellular carcinoma： analysis its clinical value
作者:
王玉峰;  曾 嘉;  何东风
Author(s):
WANG Yufeng;  ZENG Jia;  HE Dongfeng.
Department of Interventional Radiology， Affiliated Cancer Hospital of Harbin Medical University， Harbin，Heilongjiang Province 150081， China
关键词:
 ; 【关键词】 肝细胞癌; 载药微球经肝动脉化疗栓塞; 传统经肝动脉化疗栓塞
文献标志码:
A
摘要:
 【摘要】 目的 比较碘化油化疗药物乳剂联合载药微球经动脉化疗栓塞（D-TACE）和常规TACE（cTACE）治疗肝细胞癌（HCC）患者的有效性和安全性。 方法 纳入接受碘化油化疗药物乳剂联合D-TACE或cTACE治疗的HCC患者146例。57例患者作为实验组，采用碘化油化疗药物乳剂联合D-TACE+cTACE治疗，89例患者作为对照组，采用cTACE治疗。比较实验组与对照组患者的短期疗效、不良反应等。评估TACE治疗后3个月的治疗反应，并对半年内的治疗次数和治疗间隔进行分析。结果 TACE术后3个月，实验组的疾病控制率为89.50%（51/57），高于对照组的75.30%（67/89），差异有统计学意义（P=0.034）；实验组的客观缓解率为56.10%（32/57）， 对照组为46.10%（41/89），差异无统计学意义（P=0.235）。不良反应情况，呕吐实验组有54例（94.7%），对照组有87例（97.8%）；发生肝脓肿实验组有4例（7.0%），对照组有1例（1.1%）；炎症反应实验组有8例（14.0%），对照组有6（6.7%）；发热实验组有14（24.6%），对照组有17（19.1%），组间比较差异均无统计学意义（均P＞0.05）；疼痛实验组有36例（63.2%），对照组28例（31.5%），差异有统计学意义（P＜0.01）。实验组与对照组6个月内按需治疗的总次数为（2.440±1.095）次和（2.312±0.878）次，差异无统计学意义（P=0.879）；首次TACE与补充TACE的时间间隔为57.0（49.0，90.0）d和55.0（49.0，64.2） d，差异有统计学意义（P=0.045）。结论 碘化油化疗药物乳剂联合D-TACE与cTACE相比，短期疾病控制率更佳，治疗间隔较长，对肝功能的影响及术后不良反应均在可接受范围。

参考文献/References:

［1］ Sung H， Ferlay J， Siegel RL， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209-249.
［2］ Zhang ZS， Li HZ， Ma C， et al. Conventional versus drug- eluting beads chemoembolization for infiltrative hepatocellular carcinoma： a comparison of efficacy and safety［J］. BMC Cancer， 2019， 19： 1162.
［3］ Huang J， Huang W， Zhan M， et al. Drug- eluting bead trans-arterial chemoembolization combined with FOLFOX- based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma［J］. J Hepatocell Carcinoma， 2021， 8： 1445-1458.
［4］ Xue T， Le F， Chen R， et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters： a large cohort study［J］. Med Oncol， 2015， 32：64.
［5］ Song MJ， Park CH， Kim JD， et al. Drug- eluting bead loaded with doxorubicin versus conventional lipiodol- based transarterial chemoembolization in the treatment of hepatocellular carcinoma： a case- control study of Asian patients［J］. Eur J Gastroenterol Hepatol， 2011， 23： 521-527.
［6］ Huang YH， Wu JC， Chen SC， et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter［J］. Aliment Pharmacol Ther， 2006， 23： 129-135.
［7］ Zhang X， Lin X， Qiu H， et al. An investigation of efficacy， safety， and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres?誖microspheres in treating Chinese hepatocellular carcinoma patients［J］. J Clin Lab Anal， 2019， 33： e22975.
［8］ Gomes AS， Monteleone PA， Sayre JW， et al. Comparison of triple- drug transcatheter arterial chemoembolization（TACE） with single- drug TACE using doxorubicin- eluting beads： long- term survival in 313 patients［J］. AJR Am J Roentgenol， 2017， 209： 722-732.
［9］ Zhou Y. Drug- eluting bead transarterial chemoembolization is efficient and well- tolerated in treating elderly Chinese hepatocellular carcinoma patients［J］. Int J Clin Exp Pathol， 2018， 11： 4867-4878.
［10］ Yoshimitsu K. Transarterial chemoembolization using iodized oil for unresectable hepatocellular carcinoma： perspective from multistep hepatocarcinogenesis［J］. Hepat Med， 2014， 6： 89-94.
［11］ Golfieri R， Giampalma E， Renzulli M， et al. Randomised controlled trial of doxorubicin- eluting beads vs conventional chemoembolisation for hepatocellular carcinoma［J］. Br J Cancer， 2014， 111： 255-264.
［12］ Kang YJ， Lee BC， Kim JK， et al. Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/A hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol， 2020， 43： 55-64.
［13］ Li J， Wang N， Shi C， et al. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma［J］. J Cancer Res Ther， 2021， 17： 733-739.
［14］ Melchiorre F， Patella F， Ierardi AM. DEB-TACE： a standard review［J］. Future Oncol， 2018， 14： 2969-2984.
［15］ 张 训， 徐燕能， 张向琼， 等. CalliSpheres载药微球联合碘化油治疗大肝癌14例［J］． 介入放射学杂志， 2020， 29：39- 44．
［16］赵邦利， 崔新江， 邢 辉， 等. 碘化油联合微球经导管肝动脉化疗栓塞治疗大肝癌效果观察［J］. 山东医药， 2018， 58：87-89.
［17］ 李 红， 尹 芳， 罗贯虹，等. CalliSpheres载药脂微球联合TACE与传统TACE治疗肝癌疗效对比分析［J］. 胃肠病学和肝病学杂志， 2019， 28：171-174.
［18］ Shimose S， Iwamoto H， Tanaka M， et al. Increased arterio-portal shunt formation after drug- eluting beads TACE for hepatocellular carcinoma［J］. Oncology， 2020， 98： 558-565.
［19］ Kloeckner R， Weinmann A， Prinz F， et al. Conventional trans-arterial chemoembolization versus drug- eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.［J］. BMC Cancer， 2015， 15：465.
［20］ Liu YS， Lin CY， Chuang MT， et al. Five- year outcome of conventional and drug- eluting transcatheter arterial chemoembo-lization in patients with hepatocellular carcinoma［J］. BMC Gastroenterol， 2018， 18： 124.
［21］ Li H， Wu F， Duan M， et al. Drug- eluting bead transarterial chemoembolization（TACE） vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history： a comparison of efficacy and safety［J］.Medicine（Baltimore）， 2019， 98：e15314.
［22］ Shao G， Zou Y， Lucatelli P， et al. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization［J］. Ann Transl Med， 2021， 9： 714.

相似文献/References:

[1].Spontaneous regression of a giant basilar artery aneurysm in a young adult after surgical injury ：case report and literature review[J].介入放射学杂志,2007,(10):718.
　ZHANG He,LI Ming-hua,WANG Chun,et al.Spontaneous regression of a giant basilar artery aneurysm in a young adult after surgical injury ：case report and literature review[J].journal interventional radiology,2007,(08):718.
[2]李统怀,郑红枫. 子宫动脉栓塞治疗子宫瘢痕妊娠１１例[J].介入放射学杂志,2011,(11):898.
　LI Tong-huai,ZHENG Hong-feng..Clinical application of uterine artery embolization in treating uterine scar pregnancy[J].journal interventional radiology,2011,(08):898.
[3]吕维富,张爱武,周春泽,等. 子宫动脉的三维DSA表现及其最佳显示体位探讨[J].介入放射学杂志,2011,(11):853.
　LV Wei-fu,ZHANG Ai-wu,ZHOU Chun-ze,et al.3D-DSA findings of uterine artery and its optimal projection position[J].journal interventional radiology,2011,(08):853.
[4]张 靖,周少毅,陈昆山,等.经导管动脉硬化栓塞联合注射硬化治疗婴儿颌面部巨大高流量血管瘤[J].介入放射学杂志,2011,(11):848.
　ZHANG Jing,ZHOU Shao-yi,CHEN Kun-shan,et al.Transcatheter arterial sclerosing embolization with injection sclerotherapy for the treatment of huge and high-flow maxillofacial hemangiomas in infants[J].journal interventional radiology,2011,(08):848.
[5]谢小西,吕银祥,章宏欣,等. 肝动脉化疗栓塞、射频消融联合１２５Ⅰ粒子植入 治疗原发性肝癌的临床应用[J].介入放射学杂志,2011,(11):863.
　XIE Xiao-xi,LV Yin-xiang,ZHANG Hong-xin,et al.The clinical application of TACE together with RFA and 125Ⅰ seed implantation in treating hepatocellular carcinoma[J].journal interventional radiology,2011,(08):863.
[6]王铭义,王 峰. 脑灌注成像在颈动脉狭窄介入治疗中的应用[J].介入放射学杂志,2011,(11):915.
　WANG Ming-yi,WANG Feng..Application of brain perfusion imaging in interventional treatment of carotid artery stenosis[J].journal interventional radiology,2011,(08):915.
[7]杜 猛,张锦生. 介入治疗急性深静脉血栓的临床观察[J].介入放射学杂志,2011,(11):858.
　DU Meng,ZHANG Jing-sheng..Interventional therapy for acute deep venous thrombosis: a clinical observation[J].journal interventional radiology,2011,(08):858.
[8]孟庆娜,李国庆,白晓冬. 急性心肌梗死介入治疗术中恶心呕吐的护理[J].介入放射学杂志,2011,(11):913.
　MENG Qing-na,LI Guo-qing,BAI Xiao-dong..The nursing care of nausea and vomiting occurred in interventional treatment for acute myocardial infarction[J].journal interventional radiology,2011,(08):913.
[9]王海亭,蒋忠仆,周 毅,等. 透视引导下鱼肝油酸钠泡沫硬化剂治疗下肢静脉曲张３０例[J].介入放射学杂志,2011,(11):905.
　WANG Hai-ting,JIANG Zhong-pu,ZHOU Yi,et al.Fluoroscopically-guided foam sclerotherapy with sodium morrhuate for the treatment of lower extremity varices[J].journal interventional radiology,2011,(08):905.
[10]杜 鲲,管 生,胡小波,等. 原发性肝癌ＴＡＣＥ术后完全缓解病灶磁共振 ＡＤＣ值可重复性及一致性研究[J].介入放射学杂志,2011,(11):867.
　DU Kun,GUAN Sheng,HU Xiao-bo,et al.Magnetic resonance apparent diffusion coefficient values of the completely remitted lesions of primary hepatocellular carcinoma after TACE: a study of their repeatability and consistency[J].journal interventional radiology,2011,(08):867.
[11]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(08):974.
[12]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(08):177.
[13]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(08):206.
[14]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(08):333.
[15]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(08):469.
[16]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(08):636.
[17]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(08):381.
[18]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(08):520.
[19]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(08):908.
[20]易长虹,袁琳波,钱 坤,等.肝动脉灌注3-溴丙酮酸阻断大鼠肝癌能量代谢的实验研究[J].介入放射学杂志,2013,(12):1027.
　YI Chang? hong,YUAN Lin? bo,QIAN Kun,et al. Hepatic arterial infusion of 3?蛳 bromopyruvate to block up the energy metabolism of hepatic carcinoma： an experimental study in rats[J].journal interventional radiology,2013,(08):1027.

备注/Memo

备注/Memo:
（收稿日期：2022-01-19）
（本文编辑：新 宇）
更新日期/Last Update: 2022-09-27